Navigation Links
New Research Shows Promise in Using Traditional Research Methods to Assess Efficacy of Complementary Therapies
Date:11/12/2009

MINNEAPOLIS/ST. PAUL, Nov. 12 /PRNewswire/ -- New research findings presented today at the Society for Integrative Oncology's (SIO) Sixth International Conference in New York show promise in assessing the efficacy and safety of complementary and alternative medicine (CAM) using traditional research methods. Susan Sencer, MD, Medical Director, Hematology/Oncology at Children's Hospitals and Clinics of Minnesota (Children's), presented findings on the use of the homeopathic agent Traumeel S® in children with mucositis undergoing stem cell transplantation (SCT). Investigated by the Children's Oncology Group, the multi-center randomized placebo controlled trial is the first large-scale pediatric oncology trial of a CAM treatment.

Mucositis is a painful side effect of many cancer treatment regimens. Mucositis can cause intense pain, infection and the inability to eat, drink or swallow, and there are few known treatments for the condition. A small pilot study of the homeopathic agent Traumeel S® had previously shown promise in treating and preventing this serious complication of cancer therapy. Results of the current larger study did not confirm the earlier study, but showed the potential for CAM therapies to be evaluated using the same methodology as other medical treatments. Mainstream medicine relies upon conventional, validated research methods such as the randomized, blinded controlled trial to help guide clinical practice; CAM methods have not always been easily evaluated with these techniques, contributing to CAM's lack of acceptance by many physicians.

"We know complementary treatments can be very helpful for pediatric patients, but there is limited research to support our clinical observations," said Dr. Sencer. "While we found this treatment to be ineffective for mucositis, I'm excited about the potential this trial has for the future of complementary and alternative medicine research."

The 190 eligible patients in the trial received either Traumeel S® or a placebo five times daily as a swish and swallow rinse for the treatment. Results showed Traumeel S® to be ineffective at preventing and treating mucositis in SCT patients. No adverse events were found to be related to use of the study drug.

At Children's, CAM is often used in pediatric oncology patients to reduce pain, discomfort and other side-effects associated with treating cancer. The Hematology/Oncology Program at Children's is the largest in the upper Midwest with treatment outcomes that consistently rank Children's as one of the top ten programs in the U.S. The Integrative Medicine Program at Children's, which combines the best of complementary and conventional medical therapies, is the largest, longest-running pediatric, clinical integrative medicine program in North America.

About Children's Hospitals and Clinics of Minnesota

Serving as Minnesota's children's hospital since 1924, Children's Hospitals and Clinics of Minnesota is the seventh-largest pediatric health care organization in the United States, with 332 staffed beds at its two hospitals in St. Paul and Minneapolis. An independent, not-for-profit health care system, Children's of Minnesota provides care through more than 14,000 inpatient visits and more than 200,000 emergency room and other outpatient visits every year. Children's is the only Minnesota hospital system to provide comprehensive care exclusively to children. For more information, visit www.childrensmn.org.

SOURCE Children's Hospitals and Clinics of Minnesota


'/>"/>
SOURCE Children's Hospitals and Clinics of Minnesota
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
3. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
4. Researchers at Cleveland Clinic Identify Site of Dysfunction in HDL, Carrier of Good Cholesterol
5. Video: New Research Discovers Independent Brain Networks Control Human Walking
6. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
7. Cleveland Clinic Researchers Identify Mechanism Behind Platelet Function and Potentially Fatal Blood Clot Formation
8. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
9. Diabetes Research Institute Invention Promotes Growth of Stem Cells into Insulin-Producing Cells
10. Researchers Identify Virus Possibly Responsible for Declining Honeybee Population Using 454 Sequencing Technology from Roche
11. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/28/2017)... 2017 Hill-Rom Holdings, Inc. (NYSE: HRC), will ... and webcast on Friday, November 3, 2017, beginning at ... at approximately 8:30 a.m. (CDT) / 9:30 a.m. (EDT). ... financial performance and guidance for 2018, Hill-Rom executives will ... operational performance, and long-range financial outlook through 2020. ...
(Date:9/25/2017)... AMSTERDAM , Sept. 25, 2017   ... Trial Master File solutions, today—from the IQPC Trial ... Amsterdam , NL)—announced that EastHORN Clinical Services ... its clinical programs and TMF management. EastHORN, a ... Montrium,s eTMF platform to increase transparency to enable ...
(Date:9/22/2017)... Sept. 22, 2017 AVACEN Medical (AVACEN) announced ... now successfully helping those with the widespread pain associated ... diagnosed Amanda in Essex, England ... my hair, experiencing no sleep at all, tremendous pain, ... I cannot recommend [the AVACEN 100] enough, how this ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... As health professionals work ... as “patient engagement.” The patient is doing more than filling out a survey; in ... “There is an increasing emphasis in health care and research on the importance of ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... PurhealthRX ... CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil will ... and providing a CBD form that can be easily incorporated into liquid products, while ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term ... long-term care insurance companies have a waiver for care if the client has a ... when the family pays for care, is often waived, so the benefits from their ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Yisrayl Hawkins, Pastor ... that explains one of the most popular and least understood books in the Holy ... and puzzling descriptions that have baffled scholars for centuries. Many have tossed it off ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... “America On ... Christian identity. “America On The Brink” is the creation of published author, William ... several great-grandchildren. As a WWII veteran, he spent thirty years in the Navy. ...
Breaking Medicine News(10 mins):